You are here:
Two key factors set the Vaccine Alliance apart from other actors in the field of international health aid:
In this section, we explain Gavi’s unique business model and the six ways it delivers "added value".
Donor and developing countries need to see proof of the value of new vaccines before investing.
Immunisation is a commitment for life that requires guaranteed, long-term funding.
Developing countries decide for themselves how best to use Gavi support for immunisation.
It's not enough to buy new vaccines. They have to safely reach every child.
Gavi’s market shaping efforts aim to make life-saving vaccines and other immunisation products more accessible and affordable for lower-income countries.
National immunisation programes must survive long after Gavi support stops.
Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.
25 April 2016
Vaccine development needs global alliance
26 February 2016
Zika and Ebola: A taste of things to come?
03 March 2015
Ebola vaccine research in Africa
02 October 2013
Laos becomes first South East Asian nation to introduce pneumococcal vaccine
04 May 2013
Sojo Stories: Immunizing 250 Million Children By 2015
27 March 2013
Seth Berkley on Immunization in Pakistan
Heartfile eForum Blog
Concerned about the misuse of Gavi resources? Report it now.
© Gavi 2016
modal window here